Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

Eitemau Tebyg

• Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
  gan: Vickers, A, et al.
  Cyhoeddwyd: (2010)
• Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
  gan: Vickers, A, et al.
  Cyhoeddwyd: (2010)
• Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
  gan: Lilja, H, et al.
  Cyhoeddwyd: (2011)
• A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
  gan: Vickers, A, et al.
  Cyhoeddwyd: (2011)
• Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
  gan: Ulmert, D, et al.
  Cyhoeddwyd: (2008)